FOLFIRINOX regimen: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[fluorouracil]], [[irinotecan hydrochloride]], [[Folinic acid|leucovorin calcium]] and [[oxaliplatin]] used for the treatment of [[pancreatic cancer]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C11764&ns=NCI_Thesaurus>{{cite journal| author=Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M| title=The role of the FOLFIRINOX regimen for advanced pancreatic cancer. | journal=Curr Oncol Rep | year= 2013 | volume= 15 | issue= 2 | pages= 182-9 | pmid=23341367 | doi=10.1007/s11912-012-0290-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23341367 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[fluorouracil]], [[irinotecan hydrochloride]], [[Folinic acid|leucovorin calcium]] and [[oxaliplatin]] used for the treatment of [[pancreatic cancer]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C11764&ns=NCI_Thesaurus>{{cite journal| author=Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M| title=The role of the FOLFIRINOX regimen for advanced pancreatic cancer. | journal=Curr Oncol Rep | year= 2013 | volume= 15 | issue= 2 | pages= 182-9 | pmid=23341367 | doi=10.1007/s11912-012-0290-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23341367 }} </ref> | ||
==Regimen== | ==Regimen== |
Revision as of 18:15, 26 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Fluorouracil/irinotecan/leucovorin calcium/oxaliplatin; Fluorouracil with Irinotecan Hydrochloride, Leucovorin Calcium and Oxaliplatin; Folfirinox Protocol; Folfirinox Regimen
Overview
FOLFIRINOX regimen refers to a regimen consisting of fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin used for the treatment of pancreatic cancer.[1]
Regimen
FOLLeucovorin calcium (Folinic acid)
FIFluorouracil
RIIrinotecan hydrochloride
OXOxaliplatin
Indications
References
- ↑ {{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C11764&ns=NCI_Thesaurus>Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M (2013). "The role of the FOLFIRINOX regimen for advanced pancreatic cancer". Curr Oncol Rep. 15 (2): 182–9. doi:10.1007/s11912-012-0290-4. PMID 23341367.
- ↑ Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M (2013). "The role of the FOLFIRINOX regimen for advanced pancreatic cancer". Curr Oncol Rep. 15 (2): 182–9. doi:10.1007/s11912-012-0290-4. PMID 23341367.